Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Legal Officer | August 30, 2024 | September 03, 2024 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP,Corp Affairs & Gen Counsel | June 10, 2022 | June 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date August 30, 2024 · Filed September 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,140 |
Reported balance
After 2024-08-30 transaction · row 1
1 source rowRow 1 · 2024-08-30 · Grant · Acquired 33,140 · Balance 33,140 F1: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.08 · Expires 2034-08-30 | Direct | 51,039 |
Reported balance
After 2024-08-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-30 · Grant · Acquired 51,039 · Balance 51,039 F2: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company. |
Filing footnotes · ownership attribution and instrument terms
F1: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company.
F2: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company.
GILEAD SCIENCES, INC.
Report date June 10, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,426 |
Ending reported balance
After 2022-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-10 · Exercise / conversion · Acquired 782 · Balance 33,706 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2022-06-10 · Tax withholding · Disposed 280 · Balance 33,426 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 16,519 |
Reported balance
After 2022-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-10 · Exercise / conversion · Disposed 782 · Balance 16,519 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2024 Filed Sep 3, 2024 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 51,039 | $0.00 Strike: $57.08 | $0.00 |
DisclosureSEC source: 0001127602-24-023331 · form4.xml · derivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,039 Underlying: Common Stock · 51,039 shares Expires 2034-08-30 F2 · kind: Inducement grant comprised of stock options to purchase shares of common stock subject to time lapse vesting. 25% of the stock options vest on the 1-year anniversary of the grant date and the remaining 75% of the stock options vest in equal monthly installments over the subsequent 3 years to the 1-year anniversary of the grant date, with each installment vesting subject to the grantee's continued employment with the company. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 33,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023331 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,140 F1 · kind: Inducement grant comprised of restricted stock units ("RSUs") that are converted into shares of common stock on a 1:1 basis upon time based vesting. 40% of the RSUs vest on the 1-year anniversary of the grant date, an additional 40% of the RSUs vest on the 2-year anniversary of the grant date, and the remaining 20% of the RSUs vest on the 3-year anniversary of the grant date, in each case subject to the grantee's continued employment with the company. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017328 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,519 Underlying: Common Stock · 782 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 280 | $60.74 | $17,007.20 |
DisclosureSEC source: 0001127602-22-017328 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,426 Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017328 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 01:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,634 | $58.24 | $211,644.16 |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,576 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · derivative · entry 6 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,301 Underlying: Common Stock · 3,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,431 Underlying: Common Stock · 2,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,089 | $57.92 | $120,994.88 |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,210 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 15, 2022 Filed Apr 14, 2022 00:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 348 | $52.13 | $18,141.41 |
DisclosureSEC source: 0001127602-22-011955 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,924 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2021 through February 15, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,691 | $63.89 | $108,037.99 |
DisclosureSEC source: 0001127602-22-004516 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,576 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003846 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,024 Underlying: Common Stock · 2,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,036 | $63.90 | $66,200.40 |
DisclosureSEC source: 0001127602-22-003846 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,267 Read SEC document |
| February 06, 2022 Filed Feb 9, 2022 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003846 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 23:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,061 | $68.54 | $963,681.88 |
DisclosureSEC source: 0001127602-22-003048 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,576 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan dated May 28, 2021. F2 · price: Sale prices reported for the transaction reported here range from $68.34 to $68.76. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,681 | $67.34 | $382,558.54 |
DisclosureSEC source: 0001127602-22-002462 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,637 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 19,742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002462 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,318 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 15,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002462 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,576 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| August 15, 2021 Filed Aug 24, 2021 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 32 | $55.08 | $1,762.56 |
DisclosureSEC source: 0001127602-21-024266 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,198 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2021 through August 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 16, 2021. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,486 | $63.36 | $94,152.96 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 F4 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 72,855 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · derivative · entry 7 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,855 Underlying: Common Stock · 72,855 shares Expires 2031-03-10 F7 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 12,520 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · derivative · entry 6 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,751 Underlying: Common Stock · 12,520 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F6 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F6 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,231 Underlying: Common Stock · 2,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F5 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F5 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,107 | $63.91 | $70,748.37 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,652 Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 15, 2021 Filed Mar 12, 2021 23:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 334 | $56.86 | $18,990.07 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2021. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,975 | $67.41 | $133,134.75 |
DisclosureSEC source: 0001127602-21-005277 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,832 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004790 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,824 Underlying: Common Stock · 2,728 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 753 | $68.46 | $51,550.38 |
DisclosureSEC source: 0001127602-21-004790 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,807 Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004790 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,711 | $65.97 | $640,632.73 |
DisclosureSEC source: 0001127602-21-003820 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,832 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan F2 · price: Sale prices reported for the transaction reported here range from $65.73 to $66.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 01:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,736 | $66.70 | $249,191.20 |
DisclosureSEC source: 0001127602-21-002920 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,543 Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 01:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 13,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002920 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,279 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2018. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 01:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 14,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002920 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,832 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 6, 2019, and March 10, 2020. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 12,560 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · derivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,560 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,210 | $79.23 | $1,046,640.19 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F2 · price: Sale prices reported for the transactions reported here range from $79.23 to $79.24. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 650 | $24.30 | $15,791.75 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,560 | $40.56 | $509,433.60 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 10,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,552 Underlying: Common Stock · 10,370 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 61,590 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · derivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,590 Underlying: Common Stock · 61,590 shares Expires 2030-03-10 F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,950 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 2,950 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,950 | $75.55 | $222,872.50 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,950 | $24.30 | $71,670.25 |
DisclosureSEC source: 0001127602-20-010517 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,100 | $71.26 | $78,383.03 |
DisclosureSEC source: 0001127602-20-009244 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F3 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F5 · price: Sale prices reported for the transactions reported here range from $71.22 to $71.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,341 | $70.83 | $661,630.50 |
DisclosureSEC source: 0001127602-20-009244 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,744 F3 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F4 · price: Sale prices reported for the transactions reported here range from $70.21 to $71.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 15, 2020 Filed Mar 4, 2020 00:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 395 | $53.67 | $21,199.26 |
DisclosureSEC source: 0001127602-20-009244 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,085 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2019 through February 15, 2020. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,950 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-20-005129 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 2,950 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.